ReviewFrontiers in immunology2020
Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04627623 (Prevalence and Risk Factors of COVID-19 Infection in the Upper Silesian Agglomeration Population in 2020), which is not on this map. Cited by 157 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence and Risk Factors of COVID-19 Infection in the Upper Silesian Agglomeration Population in 2020
Who cites it
157 citing papers in PubMed, 5 syntheses or guidelines pooled it, 279 citations in OpenAlex.
- Recent advances in the diagnosis of COVID-19: a bird's eye view.Expert review of molecular diagnostics · 2021Pooled it
- SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Pooled it
- Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.Annals of oncology : official journal of the European Society for Medical Oncology · 2020Guideline
- Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review.Life sciences · 2020Pooled it
- COVID-19 and Skin Manifestations: An Overview of Case Reports/Case Series and Meta-Analysis of Prevalence Studies.Frontiers in medicine · 2020Pooled it
- Antibody therapy reverses biological signatures of COVID-19 progression.Cell reports. Medicine · 2022Trial
- COVID-19 serology in nephrology healthcare workers.Wiener klinische Wochenschrift · 2021Trial
- Systematic evaluation of IgG responses to SARS-CoV-2 spike protein-derived peptides for monitoring COVID-19 patients.Cellular & molecular immunology · 2021Trial
- Assessment of serological techniques for screening patients for COVID-19 (COVID-SER): a prospective, multicentric study.BMJ open · 2020Trial
- Advances on Sensors and Diagnostics of SARS-CoV-2 Biomarkers.Analytical chemistry · 2026Article
- Article
- Enhanced Multi-Model Deep Learning for Rapid and Precise Diagnosis of Pulmonary Diseases Using Chest X-Ray Imaging.Diagnostics (Basel, Switzerland) · 2025Article
- An Organic Electrochemical Transistor-Based Sensor for IgG Levels Detection of Relevance in SARS-CoV-2 Infections.Biosensors · 2024Article
- Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2.Diseases (Basel, Switzerland) · 2024Article
- Article
- Applications of Mass Spectrometry in the Characterization, Screening, Diagnosis, and Prognosis of COVID-19.Advances in experimental medicine and biology · 2024Article
- Faradaic Impedimetric Immunosensor for Label-Free Point-of-Care Detection of COVID-19 Antibodies Using Gold-Interdigitated Electrode Array.Biosensors · 2023Article
- Article
- SARS-CoV-2 peptides/epitopes for specific and sensitive diagnosis.Cellular & molecular immunology · 2023Article
- Microbiota dysbiosis influences immune system and muscle pathophysiology of dystrophin-deficient mice.EMBO molecular medicine · 2023Article
97 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since December 2019, the novel coronavirus, SARS-CoV-2, has garnered global attention due to its rapid transmission, which has infected more than two million people worldwide. Early detection of SARS-CoV-2 is one of the crucial interventions to control virus spread and dissemination. Molecular assays have been the gold standard to directly detect for the presence of viral genetic material in infected individuals. However, insufficient viral RNA at the point of detection may lead to false negative results. As such, it is important to also employ immune-based assays to determine one's exposure to SARS-CoV-2, as well as to assist in the surveillance of individuals with prior exposure to SARS-CoV-2. Within a span of 4 months, extensive studies have been done to develop serological systems to characterize the antibody profiles, as well as to identify and generate potentially neutralizing antibodies during SARS-CoV-2 infection. The vast diversity of novel findings has added value to coronavirus research, and a strategic consolidation is crucial to encompass the latest advances and developments. This review aims to provide a concise yet extensive collation of current immunoassays for SARS-CoV-2, while discussing the strengths, limitations and applications of antibody detection in SARS-CoV-2 research and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.